Welcome to our dedicated page for Sensei Biotherapeutics news (Ticker: SNSE), a resource for investors and traders seeking the latest updates and insights on Sensei Biotherapeutics stock.
Sensei Biotherapeutics, Inc. (SNSE) is a clinical-stage biotechnology pioneer developing tumor microenvironment-activated immunotherapies. This page aggregates all material news and regulatory disclosures about the company's innovative TMAb™ platform and clinical programs.
Investors and industry observers will find timely updates on clinical trial progress, partnership announcements, financial disclosures, and scientific developments. Our curated collection ensures efficient tracking of key milestones in Sensei's quest to create conditionally active cancer therapies.
The repository includes earnings reports, FDA communications, research collaborations, and peer-reviewed publication highlights. All content is vetted for relevance to SNSE's core focus on overcoming immune suppression in solid tumors through pH-sensitive antibody engineering.
Bookmark this page for structured access to Sensei's evolving pipeline updates and corporate announcements. Regularly refreshed content supports informed decision-making about this innovative player in next-generation immuno-oncology.
Sensei Biotherapeutics (Nasdaq: SNSE), a clinical stage biotechnology company specializing in next-generation cancer therapeutics, has announced its participation in an upcoming industry event. John Celebi, President and CEO, will be a panelist in the New Radiotherapy and Targeted Therapy Approaches discussion at the Canaccord Genuity Horizons in Oncology Virtual Conference. The panel is scheduled for Monday, April 7 at 2:00 p.m. ET.
Sensei Biotherapeutics (NASDAQ: SNSE) reported its full year 2024 financial results and clinical progress for solnerstotug, their conditionally active antibody targeting VISTA. Key clinical highlights include:
In the Phase 1/2 dose expansion study, among 21 evaluable PD-(L)1 resistant tumor patients, the combination therapy showed 14% overall response rate (3x higher than historical rates) and 62% disease control rate. The study achieved target enrollment of 60 patients, with full expansion data expected by year-end 2025.
Financial results show:
- Cash position: $41.3M as of December 31, 2024
- R&D expenses: $18.6M (vs $18.3M in 2023)
- G&A expenses: $13.0M (vs $18.8M in 2023)
- Net loss: $30.2M (vs $34.1M in 2023)
The company expects its current cash runway to extend into Q2 2026.
Sensei Biotherapeutics (NASDAQ: SNSE) has reported promising preliminary results from its Phase 1/2 trial of solnerstotug, a conditionally active antibody targeting VISTA. The drug showed significant clinical activity in PD-(L)1 resistant tumors, achieving a 14% overall response rate - nearly triple the historical rechallenge rates of ≤5%.
Key findings include:
- One durable complete response in Merkel Cell Carcinoma (MCC)
- Two partial responses in MCC and MSI-H Colorectal Cancer patients
- 62% disease control rate among 21 evaluable PD-(L)1 resistant patients
- All patients with tumor shrinkage remain on treatment
The drug demonstrated favorable safety with no dose-limiting toxicities, mostly Grade 1-2 adverse events, and only 7% cases of mild cytokine release syndrome. Subject to capital raising, Sensei plans to initiate Phase 2 studies in Q1 2026.
Sensei Biotherapeutics (Nasdaq: SNSE), a clinical stage biotechnology company specializing in next-generation cancer therapeutics, has announced its participation in Oppenheimer's 35th Annual Healthcare Life Sciences Conference. The company's President and CEO, John Celebi, will deliver a presentation at the virtual event on Tuesday, February 11, 2025, at 10:40 a.m. ET.
Interested parties can access the presentation webcast through the Investors section of Sensei's website. The replay will remain available for approximately 90 days after the event, and registration for the webcast is currently open.
Sensei Biotherapeutics (NASDAQ: SNSE) provided updates on its lead program, solnerstotug (SNS-101), a conditionally active antibody targeting VISTA in cancer treatment. The company has enrolled 45 patients in the dose expansion portion of its Phase 1/2 clinical trial, with full enrollment of approximately 60 patients expected by Q1 2025.
The trial evaluates solnerstotug both as monotherapy and in combination with Libtayo® in patients with advanced solid tumors. Most enrolled 'hot' tumor patients have either progressed on prior anti-PD-1 therapy or are PD-L1 negative. The drug continues to show good tolerability with a best-in-class pharmacokinetic profile, with dose optimization focusing on 3 and 15 mg/kg Q3W levels.
Clinical data update is expected in Q2 2025, including patient follow-up data from dose escalation cohorts. The company maintains cash runway into Q2 2026.
Sensei Biotherapeutics (Nasdaq: SNSE) announced its participation in Citi's 2024 Global Healthcare Conference. The conference will take place from December 3-5 in Miami, FL. As a clinical stage biotechnology company specializing in next-generation cancer therapeutics, Sensei's management team will be present at this significant healthcare industry event.
Sensei Biotherapeutics (NASDAQ: SNSE) reported Q3 2024 financial results and announced an organizational restructuring. The company will reduce its workforce by 46% and close its Rockville research site to focus resources on SNS-101 clinical development. Cash position stands at $47.0 million, expected to fund operations into Q2 2026. Q3 net loss was $7.3 million, with R&D expenses at $4.6 million and G&A expenses at $3.2 million. The Phase 1/2 dose expansion study for SNS-101 is approximately 50% enrolled, with clinical data expected in H1 2025.
Sensei Biotherapeutics (Nasdaq: SNSE) has announced its participation in two major scientific conferences. At PEGS Europe in Barcelona (November 5-7, 2024), Chief Scientific Officer Edward van der Horst will present on SNS-101, a conditionally active monoclonal antibody targeting VISTA in tumor microenvironment. At the SITC 39th Annual Meeting in Houston (November 6-10, 2024), Senior Director F. Donelson Smith will present a poster on spatial proteomic profiling of VISTA and PSGL-1 interactions across cancer indications.
Sensei Biotherapeutics (Nasdaq: SNSE) announced that it will present preclinical data on SNS-103 at the CRI-ENCI Eighth International Immunotherapy Conference from September 8-11, 2024. The presentation, titled 'Pre-clinical characterization of monoclonal antibodies targeting CD39 activity in the acidic tumor microenvironment,' will be given by F. Donelson Smith, Ph.D., Senior Director of Biologics Discovery & Early Development. The poster session is scheduled for September 8, 2024, from 12:05 – 2:05 p.m. EDT.
Sensei Biotherapeutics is a clinical-stage immuno-oncology company focused on developing next-generation cancer therapeutics. The presentation of preclinical data on SNS-103 suggests ongoing research and development efforts in their pipeline.
Sensei Biotherapeutics (Nasdaq: SNSE), a clinical stage immuno-oncology company, has announced its participation in two upcoming conferences in September 2024. The company will present at the H.C. Wainwright 26th Annual Global Investment Conference on September 9 at 7:00 a.m. ET, delivering a corporate presentation. Additionally, Sensei will participate in a fireside chat at the 2024 Cantor Fitzgerald Global Healthcare Conference on September 18 at 2:30 p.m. ET.
Both events will be accessible via webcast on the Investors section of Sensei's website, with replays available for approximately 90 days following the presentations. These conferences provide Sensei Biotherapeutics with opportunities to showcase their progress in developing next-generation cancer therapeutics to investors and industry professionals.
